18:28 , Nov 30, 2018 |  BC Week In Review  |  Financial News

ViaCyte attracts crossover investors for $80M series D

ViaCyte Inc. (San Diego, Calif.) announced an $80 million tranched series D round to fund development of its Type I diabetes stem cell therapies. ViaCyte President and CEO Paul Laikind declined to disclose the triggers...
05:02 , Nov 29, 2018 |  BC Extra  |  Financial News

ViaCyte attracts crossover investors for $80M series D

ViaCyte Inc. (San Diego, Calif.) announced an $80 million tranched series D round to fund development of its Type I diabetes stem cell therapies. ViaCyte President and CEO Paul Laikind declined to disclose the triggers...
17:55 , Oct 6, 2017 |  BC Week In Review  |  Financial News

SpecificiT completes seed financing

On Sept. 11, cancer company SpecificiT Pharma Inc. (Montreal, Quebec) said it completed an undisclosed seed financing in late August led by Sanderling Ventures . Accel-Rx Health Sciences Accelerator and founding investor AmorChem also participated....
21:05 , Jul 28, 2017 |  BC Week In Review  |  Financial News

PreciThera raises C$36M series A

Orphan bone disease newco PreciThera Inc. (Montreal, Canada) raised C$36 million ($28.6 million) on July 27 in an oversubscribed series A round led by Arix Bioscience. Sanderling Ventures , Fonds de solidarité FTQ, CTI Life...
22:01 , Jul 27, 2017 |  BC Extra  |  Financial News

PreciThera raises C$36M in series A

Orphan bone disease newco PreciThera Inc. (Montreal, Canada) raised C$36 million ($28.6 million) in an oversubscribed series A round led by Arix Bioscience. Sanderling Ventures , Fonds de solidarité FTQ, CTI Life Sciences Fund and...
22:53 , May 26, 2017 |  BioCentury  |  Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
02:04 , Dec 1, 2016 |  BC Innovations  |  Emerging Company Profile

Safe arrest

Although antimitotics remain a staple in cancer therapy for their ability to kill rapidly dividing cells, their high toxicity in normal, non-dividing cells presents a large side effect burden to patients. Diazon Pharmaceuticals Inc ....
18:29 , Nov 18, 2016 |  BC Week In Review  |  Financial News

Glycomine completes venture financing

Glycomine raised $12 million in a series A round led by Sanderling Ventures . Chiesi Ventures and individual investors also participated. Glycomine Inc. , San Francisco, Calif. ...
18:47 , Nov 16, 2016 |  BC Extra  |  Financial News

Glycomine raises $12M in series A round

Rare disease company Glycomine Inc. (San Francisco, Calif.) raised $12 million in a series A round led by Sanderling Ventures and Chiesi Ventures. The company's preclinical lead program is substrate replacement therapy Lipo-M1P to treat...
07:00 , May 16, 2016 |  BioCentury  |  Finance

Global ambitions

European biotechs not only missed out on the extended bull market that allowed U.S. biotechs to fill their coffers, but also on what could have been an arbitrage opportunity for U.S. investors who found domestic...